FELICIONI, LARA BARBARA
FELICIONI, LARA BARBARA
DIPARTIMENTO DI MEDICINA E SCIENZE DELL'INVECCHIAMENTO
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
2012-01-01 Schirosi, L; Nannini, N; Nicoli, D; Cavazza, A; Valli, R; Buti, S; Garagnani, L; Sartori, G; Calabrese, F; Marchetti, Antonio; Buttitta, Fiamma; Felicioni, LARA BARBARA; Migaldi, M; Rea, F; Di Chiara, F; Mengoli, Mc; Rossi, G.
AKT1(E17K) in human solid tumours
2008-01-01 Bleeker, Fe; Felicioni, LARA BARBARA; Buttitta, Fiamma; Lamba, S; Cardone, L; Rodolfo, M; Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Grammastro, Md; Sciarrotta, Mariagrazia; Zanon, C; Marchetti, Antonio; Bardelli, A.
Assessing EGFR mutations.
2006-01-01 Marchetti, Antonio; Felicioni, LARA BARBARA; Buttitta, Fiamma
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment
2014-01-01 Marchetti, Antonio; Del Grammastro, Maela; Felicioni, Lara; Malatesta, Sara; Filice, Giampaolo; Centi, Irene; De Pas, Tommaso; Santoro, Armando; Chella, Antonio; Brandes, Alba Ariela; Venturino, Paola; Cuccurullo, Franco; Crinò, Lucio; Buttitta, Fiamma
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
2011-01-01 Marchetti, Antonio; Felicioni, LARA BARBARA; Malatesta, Sara; Sciarrotta, Mariagrazia; Guetti, Luigi; Chella, A; Viola, Patrizia; Pullara, C; Mucilli, Felice; Buttitta, Fiamma
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
2009-01-01 Marchetti, Antonio; Milella, M; Felicioni, LARA BARBARA; Cappuzzo, F; Irtelli, L; DEL GRAMMASTRO, Maela; Sciarrotta, Mariagrazia; Malatesta, Sara; Nuzzo, C; Finocchiaro, G; Perrucci, B; Carlone, D; Gelibter, Aj; Ceribelli, A; Mezzetti, Andrea; Iacobelli, Stefano; Cognetti, F; Buttitta, Fiamma
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications.
2012-01-01 Marchetti, Antonio; DEL GRAMMASTRO, Maela; Filice, Giampaolo; Felicioni, LARA BARBARA; Giulio, Rossi; Paolo, Graziano; Giuliana, Sartori; Alvaro, Leone; Malatesta, Sara; Michele, Iacono; Luigi, Guetti; Patrizia, Viola; Mucilli, Felice; Cuccurullo, Franco; Buttitta, Fiamma
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting
2005-01-01 Marchetti, Antonio; Barassi, Fabio; Felicioni, LARA BARBARA; Martella, Carla; Salvatore, S; Mezzetti, Andrea; Cuccurullo, Franco; Buttitta, Fiamma; Chella, A; Camplese, Pierpaolo; Iarussi, T; Mucilli, Felice; Sacco, Rocco
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
2007-01-01 Barbareschi, M; Buttitta, Fiamma; Felicioni, LARA BARBARA; Cotrupi, S; Barassi, Fabio; DEL GRAMMASTRO, Maela; Ferro, A; Dalla Palma, P; Galligioni, E; Marchetti, Antonio
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.
2012-01-01 Milella, M; Nuzzo, C; Bria, E; Sperduti, I; Visca, P; Buttitta, Fiamma; Antoniani, B; Merola, R; Gelibter, A; Cuppone, F; D'Alicandro, V; Ceribelli, A; Rinaldi, M; Cianciulli, A; Felicioni, LARA BARBARA; Malatesta, Sara; Marchetti, Antonio; Mottolese, M; Cognetti, F.
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma.
2003-01-01 Buttitta, Fiamma; Pellegrini, C.; Marchetti, Antonio; Gadducci, A.; Cosio, S.; Felicioni, LARA BARBARA; Barassi, Fabio; Salvatore, S.; Martella, Carla; Coggi, G.; Bosari, S.
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
2005-01-01 Giglio, S; Mancini, F; Gentiletti, F; Sparaco, G; Felicioni, LARA BARBARA; Barassi, Fabio; Martella, Carla; Prodosmo, A; Iacovelli, S; Buttitta, Fiamma; Farsetti, A; Soddu, S; Marchetti, Antonio; Sacchi, A; Pontecorvi, A; Moretti, F.
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
2009-01-01 Bleeker, Fe; Lamba, S; Leenstra, S; Troost, D; Hulsebos, T; Vandertop, Wp; Frattini, M; Molinari, F; Knowles, M; Cerrato, A; Rodolfo, M; Scarpa, A; Felicioni, LARA BARBARA; Buttitta, Fiamma; Malatesta, Sara; Marchetti, Antonio; Bardelli, A.
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
2011-01-01 Molinari, F; Felicioni, LARA BARBARA; Buscarino, M; De Dosso, S; Buttitta, Fiamma; Malatesta, Sara; Movilia, A; Luoni, M; Boldorini, R; Alabiso, O; Girlando, S; Soini, B; Spitale, A; Di Nicolantonio, F; Saletti, P; Crippa, S; Mazzucchelli, L; Marchetti, Antonio; Bardelli, A; Frattini, M.
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
2009-01-01 Cappuzzo, F; Marchetti, Antonio; Skokan, M; Rossi, E; Gajapathy, S; Felicioni, LARA BARBARA; DEL GRAMMASTRO, Maela; Sciarrotta, Mariagrazia; Buttitta, Fiamma; Incarbone, M; Toschi, L; Finocchiaro, G; Destro, A; Terracciano, L; Roncalli, M; Alloisio, M; Santoro, A; Varella Garcia, M.
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
2006-01-01 Bon, G; Folgiero, V; Bossi, G; Felicioni, LARA BARBARA; Marchetti, Antonio; Sacchi, A; Falcioni, R.
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.
2009-01-01 Mancini, F; Di Conza, G; Pellegrino, M; Rinaldo, C; Prodosmo, A; Giglio, S; D'Agnano, I; Florenzano, F; Felicioni, LARA BARBARA; Buttitta, Fiamma; Marchetti, Antonio; Sacchi, A; Pontecorvi, A; Soddu, S; Moretti, F.
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer.
2009-01-01 Balakrishnan, A; Penachioni, Jy; Lamba, S; Bleeker, Fe; Zanon, C; Rodolfo, M; Vallacchi, V; Scarpa, A; Felicioni, LARA BARBARA; Buck, M; Marchetti, Antonio; Comoglio, Pm; Bardelli, A; Tamagnone, L.
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.
2001-01-01 Marchetti, Antonio; Buttitta, Fiamma; Bertacca, G; Zavaglia, K; Bevilacqua, G; Angelucci, D; Viacava, P; Naccarato, A; Bonadio, A; Barassi, Fabio; Felicioni, LARA BARBARA; Salvatore, S; Mucilli, Felice
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
2006-01-01 Buttitta, Fiamma; Barassi, Fabio; Fresu, G; Felicioni, LARA BARBARA; Chella, A; Paolizzi, D; Lattanzio, Giuseppe; Salvatore, S; Camplese, Pierpaolo; Rosini, Sandra; Iarussi, T; Mucilli, Felice; Sacco, Rocco; Mezzetti, Andrea; Marchetti, Antonio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. | 2012 | Schirosi, L; Nannini, N; Nicoli, D; Cavazza, A; Valli, R; Buti, S; Garagnani, L; Sartori, G; Calabrese, F; Marchetti, Antonio; Buttitta, Fiamma; Felicioni, LARA BARBARA; Migaldi, M; Rea, F; Di Chiara, F; Mengoli, Mc; Rossi, G. | |
| AKT1(E17K) in human solid tumours | 2008 | Bleeker, Fe; Felicioni, LARA BARBARA; Buttitta, Fiamma; Lamba, S; Cardone, L; Rodolfo, M; Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Grammastro, Md; Sciarrotta, Mariagrazia; Zanon, C; Marchetti, Antonio; Bardelli, A. | |
| Assessing EGFR mutations. | 2006 | Marchetti, Antonio; Felicioni, LARA BARBARA; Buttitta, Fiamma | |
| Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment | 2014 | Marchetti, Antonio; Del Grammastro, Maela; Felicioni, Lara; Malatesta, Sara; Filice, Giampaolo; Centi, Irene; De Pas, Tommaso; Santoro, Armando; Chella, Antonio; Brandes, Alba Ariela; Venturino, Paola; Cuccurullo, Franco; Crinò, Lucio; Buttitta, Fiamma | |
| Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. | 2011 | Marchetti, Antonio; Felicioni, LARA BARBARA; Malatesta, Sara; Sciarrotta, Mariagrazia; Guetti, Luigi; Chella, A; Viola, Patrizia; Pullara, C; Mucilli, Felice; Buttitta, Fiamma | |
| Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. | 2009 | Marchetti, Antonio; Milella, M; Felicioni, LARA BARBARA; Cappuzzo, F; Irtelli, L; DEL GRAMMASTRO, Maela; Sciarrotta, Mariagrazia; Malatesta, Sara; Nuzzo, C; Finocchiaro, G; Perrucci, B; Carlone, D; Gelibter, Aj; Ceribelli, A; Mezzetti, Andrea; Iacobelli, Stefano; Cognetti, F; Buttitta, Fiamma | |
| Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. | 2012 | Marchetti, Antonio; DEL GRAMMASTRO, Maela; Filice, Giampaolo; Felicioni, LARA BARBARA; Giulio, Rossi; Paolo, Graziano; Giuliana, Sartori; Alvaro, Leone; Malatesta, Sara; Michele, Iacono; Luigi, Guetti; Patrizia, Viola; Mucilli, Felice; Cuccurullo, Franco; Buttitta, Fiamma | |
| Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting | 2005 | Marchetti, Antonio; Barassi, Fabio; Felicioni, LARA BARBARA; Martella, Carla; Salvatore, S; Mezzetti, Andrea; Cuccurullo, Franco; Buttitta, Fiamma; Chella, A; Camplese, Pierpaolo; Iarussi, T; Mucilli, Felice; Sacco, Rocco | |
| Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. | 2007 | Barbareschi, M; Buttitta, Fiamma; Felicioni, LARA BARBARA; Cotrupi, S; Barassi, Fabio; DEL GRAMMASTRO, Maela; Ferro, A; Dalla Palma, P; Galligioni, E; Marchetti, Antonio | |
| EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. | 2012 | Milella, M; Nuzzo, C; Bria, E; Sperduti, I; Visca, P; Buttitta, Fiamma; Antoniani, B; Merola, R; Gelibter, A; Cuppone, F; D'Alicandro, V; Ceribelli, A; Rinaldi, M; Cianciulli, A; Felicioni, LARA BARBARA; Malatesta, Sara; Marchetti, Antonio; Mottolese, M; Cognetti, F. | |
| Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. | 2003 | Buttitta, Fiamma; Pellegrini, C.; Marchetti, Antonio; Gadducci, A.; Cosio, S.; Felicioni, LARA BARBARA; Barassi, Fabio; Salvatore, S.; Martella, Carla; Coggi, G.; Bosari, S. | |
| Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. | 2005 | Giglio, S; Mancini, F; Gentiletti, F; Sparaco, G; Felicioni, LARA BARBARA; Barassi, Fabio; Martella, Carla; Prodosmo, A; Iacovelli, S; Buttitta, Fiamma; Farsetti, A; Soddu, S; Marchetti, Antonio; Sacchi, A; Pontecorvi, A; Moretti, F. | |
| IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. | 2009 | Bleeker, Fe; Lamba, S; Leenstra, S; Troost, D; Hulsebos, T; Vandertop, Wp; Frattini, M; Molinari, F; Knowles, M; Cerrato, A; Rodolfo, M; Scarpa, A; Felicioni, LARA BARBARA; Buttitta, Fiamma; Malatesta, Sara; Marchetti, Antonio; Bardelli, A. | |
| Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. | 2011 | Molinari, F; Felicioni, LARA BARBARA; Buscarino, M; De Dosso, S; Buttitta, Fiamma; Malatesta, Sara; Movilia, A; Luoni, M; Boldorini, R; Alabiso, O; Girlando, S; Soini, B; Spitale, A; Di Nicolantonio, F; Saletti, P; Crippa, S; Mazzucchelli, L; Marchetti, Antonio; Bardelli, A; Frattini, M. | |
| Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. | 2009 | Cappuzzo, F; Marchetti, Antonio; Skokan, M; Rossi, E; Gajapathy, S; Felicioni, LARA BARBARA; DEL GRAMMASTRO, Maela; Sciarrotta, Mariagrazia; Buttitta, Fiamma; Incarbone, M; Toschi, L; Finocchiaro, G; Destro, A; Terracciano, L; Roncalli, M; Alloisio, M; Santoro, A; Varella Garcia, M. | |
| Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. | 2006 | Bon, G; Folgiero, V; Bossi, G; Felicioni, LARA BARBARA; Marchetti, Antonio; Sacchi, A; Falcioni, R. | |
| MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. | 2009 | Mancini, F; Di Conza, G; Pellegrino, M; Rinaldo, C; Prodosmo, A; Giglio, S; D'Agnano, I; Florenzano, F; Felicioni, LARA BARBARA; Buttitta, Fiamma; Marchetti, Antonio; Sacchi, A; Pontecorvi, A; Soddu, S; Moretti, F. | |
| Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. | 2009 | Balakrishnan, A; Penachioni, Jy; Lamba, S; Bleeker, Fe; Zanon, C; Rodolfo, M; Vallacchi, V; Scarpa, A; Felicioni, LARA BARBARA; Buck, M; Marchetti, Antonio; Comoglio, Pm; Bardelli, A; Tamagnone, L. | |
| mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. | 2001 | Marchetti, Antonio; Buttitta, Fiamma; Bertacca, G; Zavaglia, K; Bevilacqua, G; Angelucci, D; Viacava, P; Naccarato, A; Bonadio, A; Barassi, Fabio; Felicioni, LARA BARBARA; Salvatore, S; Mucilli, Felice | |
| Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. | 2006 | Buttitta, Fiamma; Barassi, Fabio; Fresu, G; Felicioni, LARA BARBARA; Chella, A; Paolizzi, D; Lattanzio, Giuseppe; Salvatore, S; Camplese, Pierpaolo; Rosini, Sandra; Iarussi, T; Mucilli, Felice; Sacco, Rocco; Mezzetti, Andrea; Marchetti, Antonio |